Replimune Group (NASDAQ:REPL – Free Report) had its target price decreased by Barclays from $50.00 to $13.00 in a research report report published on Wednesday morning, Benzinga reports. Barclays currently has an overweight rating on the stock. A number of other brokerages also recently weighed in on REPL. Wedbush reaffirmed an outperform rating and issued […]
Camber Capital Management LP increased its holdings in shares of Replimune Group, Inc. (NASDAQ:REPL – Free Report) by 24.0% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,550,000 shares of the company’s stock after acquiring an additional 300,000 shares […]
Caption Management LLC purchased a new stake in Replimune Group, Inc. (NASDAQ:REPL – Free Report) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 32,968 shares of the company’s stock, valued at approximately $766,000. Caption Management LLC owned approximately 0.06% […]
Mirae Asset Global Investments Co. Ltd. boosted its stake in Replimune Group, Inc. (NASDAQ:REPL – Free Report) by 6.0% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 29,226 shares of the company’s stock after purchasing an additional 1,649 shares […]